Recent advances in management of small-cell lung cancer

Small-cell, Lung cancer (SCLC) is a smoking-related disease with a poor prognosis. While SCLC is usually initially sensitive to chemotherapy and radiotherapy, responses are rarely Long Lasting. Frustratingly, most patients ultimately relapse, often with increasingly treatment resistant disease. Many strategies have been developed in an attempt to improve treatment outcomes, which have plateaued since the introduction of combination chemotherapy in the 1980s. These include trials of maintenance therapy, and dose intensification, the latter by means of increasing dose density, growth factor support and high dose chemotherapy with autologous stern cell rescue. None have been shown to improve patient survival. On the other hand, the integration of concurrent thoracic radiation and prophylactic cranial irradiation has improved the survival outcomes in patients with Limited disease. In extensive disease, irinotecan combined with cisplatin has shown promise in improving survival over conventional ptatinum/etoposide chemotherapy schedules and a confirmatory study is awaited. The future of SCLC treatment may however Lie with molecularly targeted therapies, such as antiangiogenesis agents and signal transduction inhibitors, which are being studied at present. (C) 2004 Elsevier Ltd. All rights reserved.